8-K: Turn Therapeutics Secures $25M Growth Capital Facility

Turn Therapeutics announced a growth capital loan facility of up to $25 million from Avenue Capital Group to extend its operational runway and advance key dermatology programs.

Summary

• Turn Therapeutics, Inc. entered into a growth capital loan facility with Avenue Venture Opportunities Fund II, L.P. for up to $25 million.
• An initial $7 million tranche was funded at closing on March 23, 2026.
• Up to an additional $8 million (Tranche 2) is available between September 1, 2026, and March 31, 2027, contingent on achieving specific clinical and financing milestones.
• A discretionary Tranche 3 of up to $10 million is available between January 1, 2027, and June 30, 2028, subject to further milestones and lender investment committee approval.
• The financing is expected to extend the company's operational runway through the mid-year readout of its Phase 2 atopic dermatitis trial and support preparation for registrational trials for GX-03.
• Proceeds from the full financing are anticipated to extend the company's runway through the end of 2027.
• The loan bears interest at an annual rate equal to the greater of (Prime Rate + 5.50%) or 12.25% and is secured by a lien on all of the company's assets.
• As part of the agreement, the company issued common stock with an aggregate value of $1.2 million to the lender (Equity Grant).
• The lender has a Conversion Option to convert up to $2 million (increasing to $3 million upon Tranche 2 funding) of outstanding principal into common stock at 80% of the trading price.
• The lender also has a Participation Right to invest up to $1 million in future equity financing transactions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it provides essential funding and extends the company's runway, crucial for a clinical-stage biotech, despite the associated debt costs and potential for dilution.

Positives

• Secures significant capital of up to $25 million, providing crucial funding for ongoing operations and drug development.
• Extends the company's operational runway through the mid-year Phase 2 atopic dermatitis readout and potentially through the end of 2027 with full funding.
• Supports the continued advancement of lead candidate GX-03 in moderate-to-severe atopic dermatitis and onychomycosis programs.
• The initial $7 million tranche provides immediate liquidity to the company.
• Avenue Capital Group's investment signals confidence in Turn Therapeutics' clinical progress and GX-03's potential across multiple indications.

Negatives

• The full $25 million is not guaranteed and is contingent on achieving specific clinical and financing milestones, including raising additional equity.
• The loan bears a high interest rate, the greater of Prime Rate + 5.50% or 12.25%, which will increase debt servicing costs.
• The loan is secured by a lien upon and security interest in all of the company's assets, including intellectual property.
• The company issued $1.2 million in common stock as an Equity Grant to the lender, causing immediate dilution to existing shareholders.
• The Conversion Option allows the lender to convert up to $2 million (or $3 million upon Tranche 2 funding) of principal into common stock at 80% of the trading price, potentially leading to further dilution at a discount.
• A final payment of 3.75% of the aggregate funded amount is due at maturity or prepayment.

Risks

• Failure to achieve specified clinical and financing milestones could prevent the company from accessing subsequent tranches of funding (Tranche 2 and Discretionary Tranche 3).
• The company's ability to execute its strategic plan and the success of its development programs are subject to inherent uncertainties and risks.
• Risks related to the timing and effectiveness of the company's registration statement.
• The loan is secured by all company assets, including intellectual property, which increases the risk for the company in case of default.
• Potential for further dilution from the lender's Conversion Option and Participation Right in future equity financings.
• The company is subject to customary events of default, including non-payment, breaches of covenants, insolvency, and the occurrence of a material adverse effect on the company.

Future Outlook

The company anticipates the initial tranche of financing will extend its operational runway through the mid-year readout of its Phase 2 atopic dermatitis trial and support preparation for registrational trials for GX-03. With the full $25 million financing, the company expects to extend its runway through the end of 2027, enabling continued advancement of its atopic dermatitis and onychomycosis programs.

Management Comments

• "This financing comes at a critical inflection point for Turn as we approach the mid-year readout of our Phase 2 trial in moderate-to-severe atopic dermatitis." Brad Burnam, Chief Executive Officer of Turn Therapeutics.
• "GX-03 has generated encouraging independent investigator-sponsored human data in onychomycosis, where effective treatment options remain limited." Brad Burnam, Chief Executive Officer of Turn Therapeutics.
• "We intend to continue advancing the onychomycosis program in parallel with delivering the Phase 2 atopic dermatitis data from our ongoing trial." Brad Burnam, Chief Executive Officer of Turn Therapeutics.
• "We are pleased to partner with Turn Therapeutics and support its development of differentiated therapies in dermatology." Chad Norman, Senior Portfolio Manager at Avenue Capital Group.
• "We were impressed by the clinical progress to date and the potential of GX-O3 across multiple indications, and we structured this facility to support the Company’s next phase of growth." Chad Norman, Senior Portfolio Manager at Avenue Capital Group.

Industry Context

StockSavvy.ai notes that securing non-dilutive (or less dilutive than pure equity) financing is a common strategy for clinical-stage biotechnology companies to extend their cash runway without immediately impacting existing shareholder value significantly. This type of growth capital loan, while carrying a higher interest rate and asset-backed security, allows Turn Therapeutics to fund critical clinical milestones for its GX-03 candidate in a competitive dermatology market, where successful Phase 2 and 3 data are crucial for valuation inflection. The focus on atopic dermatitis and onychomycosis positions Turn Therapeutics against established players and emerging biotechs in these large markets.

Comparison to Industry Standards

• The interest rate (greater of Prime + 5.50% or 12.25%) is typical for venture debt facilities provided to clinical-stage biotech companies, reflecting the inherent risk profile compared to more mature companies with revenue-generating products.
• The inclusion of an equity grant ($1.2 million) and a conversion option (up to $3 million at 80% of trading price) is standard practice in venture debt, providing lenders with an equity upside in exchange for the capital provided.
• Milestone-based tranches are common in biotech financing, aligning the release of funds with the achievement of key clinical and regulatory progress, such as positive Phase 2 data and initiation of Phase 3 trials, similar to deals seen with companies like XBiotech or smaller dermatology-focused biotechs securing development capital.
• The extension of the cash runway through 2027, if all tranches are funded, is a critical benchmark for clinical-stage companies, providing sufficient time to reach significant data readouts without immediate financing pressure, comparable to the runway targets often sought by peers like Arcutis Biotherapeutics or Dermavant Sciences during their development phases.

Stakeholder Impact

• Shareholders: Potential for dilution from the Equity Grant and Conversion Option, but also benefit from extended cash runway and continued drug development.
• Employees: Increased job security due to extended operational runway, continued work on key programs.
• Customers/Patients: Potential for new treatment options if GX-03 development is successful.
• Creditors: Avenue Capital Group becomes a significant creditor with a secured interest in all company assets.

Next Steps

• Mid-year readout of Phase 2 trial in moderate-to-severe atopic dermatitis.
• Continued advancement of the onychomycosis program.
• Preparation for registrational trials for GX-03 as a treatment for moderate-to-severe atopic dermatitis and onychomycosis.
• Achievement of clinical and financing milestones to unlock Tranche 2 and Discretionary Tranche 3 funding.
• Potential future equity financing transactions where the lender has a participation right.

Key Dates

Recommendation

The financing provides critical capital and extends the company's operational runway, which is a positive for a clinical-stage biotech. However, the terms involve significant debt, high interest rates, and potential for dilution through equity grants and conversion options. While it de-risks the immediate funding needs, the fundamental investment thesis still hinges on successful clinical trial outcomes for GX-03, which remain uncertain. Therefore, a 'hold' recommendation is appropriate for investors to monitor clinical progress and the company's ability to meet future financing milestones.

Keywords

Turn Therapeutics, TTRX, Avenue Capital Group, Growth Capital Loan, Financing, Atopic Dermatitis, Eczema, Onychomycosis, Nail Fungus, GX-03, Clinical-stage, Dermatology, Biotechnology, Debt Financing, Equity Grant, Dilution, Phase 2 Trial, Registrational Trials